Dr. Michael S. Isakoff
Claim this profileConnecticut Children's Medical Center
Expert in Tumors
Expert in Neuroblastoma
59 reported clinical trials
117 drugs studied
About Michael S. Isakoff
Education:
- Obtained MD from the University of Connecticut School of Medicine (1987).
- Completed Residency in Pediatrics at Yale-New Haven Hospital (1990).
- Finished Fellowship in Pediatric Hematology/Oncology at Yale-New Haven Hospital (1993).
Experience:
- Affiliated with Connecticut Children's Medical Center.
- Director of the Pediatric Blood and Marrow Transplant Program.
- Co-Director of the Stem Cell Research Center.
Area of expertise
1Tumors
Global LeaderStage I
Stage IV
Stage II
2Neuroblastoma
Global LeaderMYC positive
Stage IV
MYC negative
Affiliated Hospitals
Clinical Trials Michael S. Isakoff is currently running
Genetic Testing-Directed Therapy
for Pediatric Cancer
This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas.
Recruiting1 award Phase 214 criteria
Selumetinib vs. Chemotherapy
for Brain Cancer
This trial is comparing a new drug, selumetinib, with standard chemotherapy to treat patients with a specific type of brain tumor. The patients do not have a certain genetic mutation and are not affected by a genetic disorder. Selumetinib works by blocking enzymes needed for tumor growth, while the standard drugs kill or stop tumor cells from dividing.
Recruiting2 awards Phase 3
More about Michael S. Isakoff
Clinical Trial Related7 years of experience running clinical trials · Led 59 trials as a Principal Investigator · 28 Active Clinical TrialsTreatments Michael S. Isakoff has experience with
- Cyclophosphamide
- Radiation Therapy
- Etoposide
- Laboratory Biomarker Analysis
- Nivolumab
- Vincristine Sulfate
Breakdown of trials Michael S. Isakoff has run
Tumors
Neuroblastoma
Brain Tumor
Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Michael S. Isakoff specialize in?
Michael S. Isakoff focuses on Tumors and Neuroblastoma. In particular, much of their work with Tumors has involved Stage I patients, or patients who are Stage IV.
Is Michael S. Isakoff currently recruiting for clinical trials?
Yes, Michael S. Isakoff is currently recruiting for 23 clinical trials in Hartford Connecticut. If you're interested in participating, you should apply.
Are there any treatments that Michael S. Isakoff has studied deeply?
Yes, Michael S. Isakoff has studied treatments such as Cyclophosphamide, Radiation Therapy, Etoposide.
What is the best way to schedule an appointment with Michael S. Isakoff?
Apply for one of the trials that Michael S. Isakoff is conducting.
What is the office address of Michael S. Isakoff?
The office of Michael S. Isakoff is located at: Connecticut Children's Medical Center, Hartford, Connecticut 06106 United States. This is the address for their practice at the Connecticut Children's Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.